Exosomes are small extracellular vesicles present in various body fluids such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger RNA (mRNA), and micro RNA. Currently, exosomes have great potential to be used as a vehicle for drug delivery and a biomarker for the diagnosis of various diseases and for therapeutic use. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer.
The global exosome diagnostic and therapeutic market is expected to reach $367 million by 2022, growing at a CAGR of 37.8% from 2016 to 2022. Increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global exosome diagnostic and therapeutic market. Moreover, technological advancements in exosomes isolation, analytical procedures, and innovative and advanced applications of exosomes also supports to the growth of the market. Stringent government regulations for the approval of exosomes diagnostic and therapeutic products and low awareness about the applications of exosomes hamper the market growth.
The world exosomes diagnostic and therapeutic market is segmented based on application, product, end user, and geography. Based on the application, it is divided into diagnostic and therapeutic applications. Based on the product, it is classified into instrument, reagents, and software used in the isolation and analysis of exosomes from cells and tissues. Based on end user, the market is segmented into cancer institute, institutes, hospitals, diagnostic centers, and others (medical universities, and not-for-profit organizations). Geographically, the market is segmented across four major regions, such as North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, and rest of Europe), Asia-Pacific (China, Japan, and rest of Asia-Pacific) and LAMEA.
Key benefits
Key market segments
The world exosome diagnostic and therapeutic market is segmented into application, product, end user, and geography.
MARKET BY APPLICATION
MARKET BY PRODUCT
MARKET BY END USER
MARKET BY GEOGRAPHY
KEY PLAYERS
Other players in the value chain include (profiles not included in the report)
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.1.1 Top investment pockets
3.1.2 Top winning strategies
3.2 Porters Five Forces analysis
3.2.1 Bargaining power of the suppliers
3.2.2 Bargaining power of buyers
3.2.3 Threat of new entrants
3.2.4 Intensity of rivalry
3.2.5 Threat of substitutes
3.3 Market dynamics
3.3.1 Drivers
3.3.1.1 increasing prevalence of cancer
3.3.1.2 initiatives implemented by the government and non-government associations for rise in health awareness
3.3.1.3 technological advancements in exosomes isolation and analytical procedures
3.3.1.4 Innovative and advanced Applications of exosomes
3.3.2 Restraints
3.3.2.1 Technical difficulties in the usage of exosomes
3.3.2.2 Stringent regulatory requirements for the approval and commercialization of Exosome diagnostic and therapeutic products
3.3.2.3 low awareness and lack of skilled professionals required for the isolation of exosomes
3.3.3 Opportunities
3.3.3.1 developing economies offer lucarative growth opportunities
CHAPTER 4 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
4.1 Overview
4.2 Diagnostic application
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Therapeutic application
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
5.1 Overview
5.2 Instrument
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.3 Reagents
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 Software
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
CHAPTER 6 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Cancer Institutes
6.2.1 Market size and forecast
6.3 Hospitals
6.3.1 Market size and forecast
6.4 Diagnostic Centers
6.4.1 Market size and forecast
6.5 Others
6.5.1 Market size and forecast
CHAPTER 7 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY GEOGRAPHY, 2015-2022
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.2.4 U.S.: market size and forecast
7.2.5 Canada market size and forecast
7.2.6 Mexico: market size and forecast
7.3 Europe
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.3.4 Germany: market size and forecast
7.3.5 France: market size and forecast
7.3.6 U.K.: market size and forecast
7.3.7 Italy market size and forecast
7.3.8 Rest of Europe: market size and forecast
7.4 Asia-Pacific
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.4.4 Japan: market size and forecast
7.4.5 China market size and forecast
7.4.6 Rest of Asia-Pacific: market size and forecast
7.5 LAMEA
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Aethlon Medical, Inc.
8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments
8.2 Exosome Diagnostics, Inc.
8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments
8.3 NanoSomix, Inc.
8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments
8.4 Thermo Fisher Scientific, Inc.
8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments
8.5 Malvern Instruments Ltd
8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments
8.6 System Biosciences, Inc.
8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments
8.7 NX PHARMAGEN
8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments
8.8 Sistemic Ltd.
8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments
8.9 Capricor Therapeutics, Inc.
8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments
8.10 Exiqon A/S
8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments
*Other players in the value chain include (players not profiled in the report)
*Profiles of these players are not included. The same will be included on request
List of Figures
FIG. 1 TOP INVESTMENT POCKETS IN WORLD EXOSOME DAIGNOSTIC AND THERAPEUTIC MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 20142016
FIG. 3 PORTERS FIVE FORCES ANALYSIS
FIG. 4 TOP IMPACTING FACTORS: WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET
FIG. 5 NUMBER OF CANCER PATIENTS IN MAJOR COUNTRIES IN 2012 (AGE- STANDARDISED RATE PER 100,000)
FIG. 6 APPLICATIONS OF EXOSOMES
FIG. 7 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2015 & 2022 (% SHARE)
FIG. 8 WORLD EXOSOME DIAGNOSTIC MARKET, 20142022 ($THOUSAND)
FIG. 9 WORLD EXOSOME DIAGNOSTIC MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 10 WORLD EXOSOME THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 11 WORLD EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 12 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2015 & 2022 (% SHARE)
FIG. 13 WORLD INSTRUMENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, 20142022 ($THOUSAND)
FIG. 14 WORLD INSTRUMENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 15 WORLD REAGENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, 20142022 ($THOUSAND)
FIG. 16 WORLD REAGENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 17 WORLD SOFTWARE MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, 20142022 ($THOUSAND)
FIG. 18 WORLD SOFTWARE MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 19 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2015 & 2022 (% SHARE)
FIG. 20 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, 20142022 ($THOUSAND)
FIG. 21 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 22 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, 20142022 ($THOUSAND)
FIG. 23 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 24 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, 20142022 ($THOUSAND)
FIG. 25 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 26 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHER END USER, 20142022 ($THOUSAND)
FIG. 27 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHER END USER, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 28 U.S.: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 29 CANADA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 30 MEXICO: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 31 GERMANY: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 32 FRANCE: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 33 U.K.: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 34 ITALY: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 35 REST OF EUROPE: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 36 JAPAN: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 37 CHINA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 38 REST OF ASIA-PACIFIC: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 20142022 ($THOUSAND)
FIG. 39 AETHLON MEDICAL: REVENUE GENERATED, 20132015 ($MILLION)
FIG. 40 THERMO FISHER: REVENUE, 20132015 ($MILLION)
FIG. 41 THERMO FISHER - REVENUE, BY SEGMENT, 2015 (%)
FIG. 42 THERMO FISHER REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 43 CAPRICOR THERAPEUTICS, REVENUE 20132015 ($MILLION)
FIG. 44 EXIQON, REVENUE 20132015 ($MILLION)
List of Tables
TABLE 1 EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 20142022 ($THOUSAND)
TABLE 2 WORLD EXOSOME DIAGNOSTIC MARKET, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 3 EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 4 EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 20142022 ($THOUSAND)
TABLE 5 WORLD INSTRUMENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 6 WORLD REAGENTS MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 7 SOFTWARE MARKET FOR EXOSOME DIAGNOSTIC & THERAPEUTIC, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 8 EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 20142022, ($THOUSAND)
TABLE 9 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 10 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITALS, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 11 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 12 WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHER END USER, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 13 WORLD: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY GEOGRAPHY, 20142022 ($THOUSAND)
TABLE 14 NORTH AMERICA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 20142022 ($THOUSAND)
TABLE 15 NORTH AMERICA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 20142022 ($THOUSAND)
TABLE 16 NORTH AMERICA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 20142022 ($THOUSAND)
TABLE 17 NORTH AMERICA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 20142022 ($THOUSAND)
TABLE 18 EUROPE: EXOSOME DIAGNOSTIC AND THERAPEUTIC S MARKET, BY COUNTRY, 20142022 ($THOUSAND)
TABLE 19 EUROPE: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 20142022 ($THOUSAND)
TABLE 20 EUROPE: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 20142022 ($THOUSAND)
TABLE 21 EUROPE: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 20142022 ($THOUSAND)
TABLE 22 ASIA-PACIFIC: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 20142022 ($THOUSAND)
TABLE 23 ASIA-PACIFIC: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 20142022 ($THOUSAND)
TABLE 24 ASIA-PACIFIC: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 20142022 ($THOUSAND)
TABLE 25 ASIA-PACIFIC: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 20142022 ($THOUSAND)
TABLE 26 LAMEA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 20142022 ($THOUSAND)
TABLE 27 LAMEA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 20142022 ($THOUSAND)
TABLE 28 LAMEA: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 20142022 ($THOUSAND)
TABLE 29 AETHLON MEDICAL - COMPANY SNAPSHOT
TABLE 30 AETHLON MEDICAL - OPERATING SEGMENTS
TABLE 31 EXOSOME DIAGNOSTICS- COMPANY SNAPSHOT
TABLE 32 EXOSOME DIAGNOSTICS - OPERATING SEGMENTS
TABLE 33 NANOSOMIX- COMPANY SNAPSHOT
TABLE 34 NANOSOMIX - OPERATING SEGMENTS
TABLE 35 THERMO FISHER - COMPANY SNAPSHOT
TABLE 36 THERMO FISHER - OPERATING SEGMENTS
TABLE 37 MALVERN INSTRUMENTS - COMPANY SNAPSHOT
TABLE 38 MALVERN - OPERATING SEGMENTS
TABLE 39 SBI- COMPANY SNAPSHOT
TABLE 40 SYSTEM BIOSCIENCES -PRODUCT & SOLUTIONS
TABLE 41 NX PHARMAGEN- COMPANY SNAPSHOT
TABLE 42 NX PHARMAGEN PRODUCT CATEGORY
TABLE 43 SISTEMIC - COMPANY SNAPSHOT
TABLE 44 SISTEMIC SOLUTION & SERVICES
TABLE 45 CAPRICOR THERAPEUTICS- COMPANY SNAPSHOT
TABLE 46 CAPRICOR THERAPEUTICS - OPERATING SEGMENTS
TABLE 47 EXIQON- COMPANY SNAPSHOT
TABLE 48 EXIQON - OPERATING SEGMENTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
